Recursion Pharmaceuticals Inc - Class A
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Recursion Pharmaceuticals Inc - Class A
Current Price
$2.93
-3.62%GoodMoat Value
$0.63
78.5% overvaluedProfile
Valuation (TTM)
Market Cap$1.55B
P/E-2.76
EV—
P/B1.37
Shares Out527.40M
P/Sales23.27
Revenue$66.41M
EV/EBITDA—
Recursion Pharmaceuticals Inc - Class A (RXRX) Stock Analysis
Market Cap$1.55B
Current Price$2.93
P/E Ratio-2.76
Forward P/E—
PEG Ratio0.05
EPS$-1.44
Book Value$2.14
P/B Ratio1.37
RXRX Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 670M
Revenue
2M
FY19
4M
FY20
10M
FY21
40M
FY22
45M
FY23
59M
FY24
75M
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
RXRX 52-Week Range
$2.84
$6.79
50-Day MA: $3.34200-Day MA: $4.38
Did you know?
Currently near its 52-week low — in the bottom 2% of its range.
Recursion Pharmaceuticals Inc - Class A (RXRX) Financial Summary
Recursion Pharmaceuticals Inc - Class A (RXRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $2.93 with a market capitalization of $1.55B.
Key valuation metrics include a P/E ratio of -2.76, price-to-book ratio of 1.37, and EPS of $-1.44. The company reports a profit margin of -842.9% and return on equity of -49.5%.
RXRX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $1.55B |
| P/E Ratio | -2.76 |
| EPS | $-1.44 |
| P/B Ratio | 1.37 |
| P/S Ratio | 23.27 |
| Profit Margin | -842.9% |
| Return on Equity | -49.5% |
| Debt/Equity | 0.07 |
RXRX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $2.32M | $-61.88M |
| FY20 | $3.96M | $-87.01M |
| FY21 | $10.18M | $-186.48M |
| FY22 | $39.84M | $-239.48M |
| FY23 | $44.58M | $-328.07M |
| FY24 | $58.84M | $-463.66M |
| FY25 | $74.68M | $-644.76M |
Recursion Pharmaceuticals Inc - Class A (RXRX) Valuation
Based on GoodMoat's DCF model, Recursion Pharmaceuticals Inc - Class A has a fair value estimate of $0.63. At the current price of $2.93, the stock appears 364.2% overvalued relative to our intrinsic value estimate.
RXRX Quality Indicators
Recursion Pharmaceuticals Inc - Class A maintains a profit margin of -842.9% and an operating margin of -867.9%. Return on equity stands at -49.5%. The current ratio is 5.50. Debt-to-equity ratio is 0.07.
About Recursion Pharmaceuticals Inc - Class A
Recursion Pharmaceuticals Inc - Class A
RXRX Free Cash Flow
Recursion Pharmaceuticals Inc - Class A generated $-378.28M in trailing twelve-month free cash flow, representing an FCF yield of -24.48%. This low FCF yield may reflect heavy reinvestment or growth spending.
RXRX Shares Outstanding
Recursion Pharmaceuticals Inc - Class A has 0.53 billion shares outstanding at a share price of $2.93, giving it a market capitalization of $1.55B.